Current regulatory toxicology perspectives on the development of herbal medicines to prescription drug products in the United States

Food and Chemical Toxicology

Volumn 46, Issue 8, 2008, Pages 2606-2610

  Wu, Kuei Meng ^a   Ghantous, Hanan ^a   Birnkrant, Debra B ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Botanical; Carcinogenicity; Genotoxicity; Herbal; Regulatory toxicology; Reproductive toxicity

Indexed keywords

ANTIOXIDANT; ARISTOLOCHIC ACID; EPIGALLOCATECHIN GALLATE; GREEN TEA EXTRACT; HERBACEOUS AGENT; SCAVENGER; VEREGEN;

ACUTE TOXICITY; ANIMAL PRODUCT; CARCINOGENICITY; CHRONIC TOXICITY; CONDYLOMA ACUMINATUM; ENDANGERED SPECIES; GENOTOXICITY; HERBAL MEDICINE; HUMAN; MUTAGENICITY; NOMENCLATURE; NONHUMAN; PRESCRIPTION; REPRODUCTIVE TOXICITY; REVIEW; RISK BENEFIT ANALYSIS; TOXICITY TESTING; TOXICOKINETICS; TOXICOLOGY; TRADITIONAL MEDICINE; UNITED STATES;

ANIMALS; CARCINOGENICITY TESTS; HUMANS; LEGISLATION, DRUG; MEDICINE, HERBAL; MUTAGENICITY TESTS; PLANTS, MEDICINAL; PRESCRIPTIONS, DRUG; TERATOGENS; TERMINOLOGY AS TOPIC; TOXICITY TESTS; UNITED STATES;

EID: 47149089182     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2008.05.029     Document Type: Review

References (10)

1. Box R.J., and Spielmann H. Use of the dog as non-rodent test species in the safety testing schedule associated with the registration of crop and plant protection products (pesticides): present status. Arch. Toxicol. 79 (2005) 615-626
2. Chen, S., Dou, J., Temple, R., Agarwal, R., Wu, K.M., Walker, S. New therapies from old medicines - approval of the first botanical prescription drug by FDA and the challenges of developing botanical new drugs. submitted for publication.
3. Greuter, W. (Ed.), 2000. International Code of Botanical Nomenclature (St Louis Code), Koeltz Scientific Books, Königstein (International Association for Plant Taxonomy).
4. Parkinson C., Lumley C.E., and Walker S.R. The value of information generated by long-term toxicity studies in the dog for the nonclinical safety assessment of pharmaceutical compounds. Fund. Appl. Toxicol. 25 (1995) 115-123
5. Wu, K.M., 2002. Development of traditional Chinese medicine: use of endangered species and its protection. In: US Fish and Wildlife/Wildlife Conservation Society Symposium on ''The consensus conference on protecting medicinal plants and animals in oriental medicine'', New York.
6. Wu K.M., DeGeorge J., Atrakchi A., Barry E., Bigger A., Chen C., Du T., Freed L., Geyer H., Goheer A., Jacobs A., Jean D., Rhee H., Osterberg R., Schmidt W., and Farrelly J. A special update from the United States Food and Drug Administration: preclinical issues and status of investigation of botanical drug products in the United States. Toxicol. Lett. 111 (2000) 199-202
7. Wu K.M., Farrelly J., Birncrant D., Chen S., Dou J., Aisar Atrakchi A., Bigger A., Chen C., Chen Z., Freed L., Ghantous H., Goheer A., Hausner E., Osterberg R., Rhee H., and Zhang K. Regulatory toxicology perspectives on the development of botanical drug products in the United States. Am. J. Ther. 11 (2004) 213-217
8. Wu K.M., Farrelly J., Upton R., and Chen J. Complexities of the herbal nomenclature system in traditional Chinese medicine (TCM): lesson learned from the misuse of aristolochia-related species and the importance of the pharmaceutical name during botanical drug product development. Phytomedicine 14 (2007) 273-279
9. Wu K.M., Ghantous H., and Birnkrant D.B. Botanical drug development: Waiver of preclinical pharm/tox studies and importance of initial clinical trial design. FASEB J. 22 (2008) 720.3
10. Wu K.M., Ghantous H., and Birnkrant D.B. Botanical drug product development in the USA: importance of genotoxicity testing. FASEB J. 22 (2008) 720.2